Ra Pharmaceuticals Plummets on Phase II Initial Clinical Trial Data, What You Need to...

Ra Pharmaceuticals Inc (NASDAQ: RARX) shares ended down just over 20% today. The stock’s plummet was primarily attributed to its announcement of initial data from its Phase II clinical program for...
Celsion

Celsion Shares Up Over 7% After Cancellation of Registered Direct Offering

Celsion Corporation (NASDAQ: CLSN) shares were up over 7% today, after the company announced that it cancelled its registered direct offering of common stock. That said, this action would not dilute...

Vanda Pharmaceuticals Ended Up Over 8%, and Here’s What You Need Know

Vanda Pharmaceuticals Inc (NASDAQ: VNDA) shares were up over 8% today, after an investment company filed an SEC Schedule 13G. Additionally, there were other insiders who filed SEC Form 4s. That...
Rigel

Here’s What You Need to Know About Rigel’s Strong Performance Today…

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares were up over 10% on the day, after the company announced that the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application...

Celsion Withdrawing From Stock Offering and Shares Rise Over 50%, Here’s What You Need...

Celsion Corporation (NASDAQ:CLSN) shares were up over 50% today, after the company filed a request to withdraw registration statement on Form S-1. That said, this was the primary catalyst that sent...

Epizyme Had A Volatile Session, and Here’s What You Need to Know…

Epizyme Inc (NASDAQ: EPZM) shares ended up over 10% today, but it was a volatile session for the clinical-stage biopharmaceutical company. The company sold off shortly after the open, after it...

What You Need to Know About Clinical Trials for Biotech Stocks

Let’s face it...biotech stocks are difficult to understand when you’re first starting out. Biotech stocks are volatile, and your account could suffer, if you don’t know what you’re looking for or...

Here’s What You Need to Know About Omeros’ Rise

Omeros Corporation (NASDAQ:OMER) ended the up nearly 15%, after the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation today. Let's get right into the catalyst and discuss some reasons...

GTx Shares Nearly Doubles Following Announcement of Phase II Proof-of-Concept Trial Data

GTx, Inc. (NASDAQ:GTXI) shares ended the day up over 90% due to the company’s announcement of its release of preliminary clinical data from its open-label, ongoing Phase II clinical trial of...
XBIT

XBiotech Plummets Over 60% After Discontinuation of Phase III Study, Here’s What You Need...

XBiotech Inc(NASDAQ: XBIT) shares were down over 60% today, after the company filed an SEC Form 8-K Filing shortly before the close. Now, the stock plummeted primarily due to its announcement...

Hot Stocks